Polaryx Therapeutics, Inc. PLYX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|
| —— | —— | $6.82M+143% | ||
| —— | —— | $1.49M-3.2% | ||
| —— | —— | $8.32M+91.1% | ||
| —— | —— | $8.32M+91.1% | ||
| —— | —— | -$8.32M-91.1% | ||
| —— | —— | -$27.82M+8.4% | ||
| —— | —— | -$0.78+12.6% | ||
| —— | —— | -$0.78+12.6% | ||
| —— | —— | —— | ||
| —— | —— | —— | ||
| $1.46M+25.3% | $1.16M— | —— | ||
| —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Polaryx Therapeutics, Inc. profitable?
- Polaryx Therapeutics, Inc. is not currently profitable: it reported a net loss of $22.8M over the trailing twelve months.
- What is Polaryx Therapeutics, Inc. 's earnings per share?
- Polaryx Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-0.60.
- Where does Polaryx Therapeutics, Inc. 's income statement data come from?
- Every line is extracted from Polaryx Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.